

Sanofi US
55 Corporate Dr.
Mail Stop 55C-200
Bridgewater, NJ 08807
United States

April 22, 2019

NCCN®
National Comprehensive Cancer Network
275 Commerce Dr.
Suite 300
Fort Washington, PA 19034
submissions@nccn.org

Dear Sir or Madame,

On behalf of Sanofi U.S., we would like to request the addition of **THYROGEN® (thyrotropin alfa)** to NCCN®. **THYROGEN®** received FDA approval on **November 30, 1998**. It is a **recombinant form of human thyroid stimulating hormone indicated as an adjunctive diagnostic tool for serum thyroglobulin testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy and as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer**. We kindly ask that you please review the enclosed **THYROGEN** prescribing information for inclusion of **thyrotropin alfa** in NCCN®.

If you have any questions or require additional information, please do not hesitate to contact Sanofi US Medical Information Services.

Thank you for your time and consideration.

Sincerely,

Sanofi US Medical Information

Enclosures: 2
Product Prescribing Information
Cover Letter